

Supplementary Table 1

Socio-demographic and clinical characteristics of the sample at baseline.

		REHACOP group (n = 42)		Active control group (n = 39)		<i>t/U/X²</i>	<i>p</i>
		Mean n (%)	SD	Mean n (%)	SD		
Age (years)		41.88	10.11	42.13	10.88	0.106	.916
Education (years)		10.3	2.42	10.15	2.98	772.00	.654
Gender	Males	36 (85.7%)		30 (76.9%)		1.04	.309
	Females	6 (14.3%)		9 (23.1%)			
Handedness	Right-handed	33 (78.6%)		32 (82.1%)		3.051	.217
	Left-handed	0 (0%)		2 (5.1%)			
	Mixed-handed	9 (21.4%)		5 (12.8%)			
Age of onset (years)		24.07	5.92	23.21	7.43	712.00	.311
Previous hospitalizations		6.26	6.63	7.94	7.87	733.00	.414
Hospitalization status	Outpatients	22 (52.4%)		19 (48.7%)		0.109	.742
	Inpatients	20 (47.6%)		20 (51.3%)			
Medication dosage		514.70	298.98	482.84	196.61	805.00	.895
Premorbid IQ		95.62	10.02	93.97	9.99	706.00	.284

SD = Standard Deviation; *t* = *t*-test; *U* = Mann-Whitney *U*; *X*² = Chi-squared;

Medication dosage refers to chlorpromazine equivalent doses (mg/day).

Supplementary Table 2

Neurocognitive, creativity, and social cognitive performance in the REHACOP and Active Control groups at baseline and post treatment.

		REHACOP group		Active control group		Baseline comparison	
		(n = 42)		(n = 39)			
		Mean (95% CI)	SD	Mean (95% CI)	SD	<i>t/U</i>	<i>p</i>
Neurocognition							
CF							
	Pre	0.06 (-0.17 to 0.29)	0.74	-0.06 (-0.39 to 0.25)	1.03	803.50	.883
	Post	0.15 (-0.08 to 0.37)	0.71	-0.16 (-0.49 to 0.16)	1.07		
PS							
	Pre	0.20 (-0.08 to 0.49)	0.88	-0.21 (-0.45 to 0.01)	0.71	2.30	.024
	Post	0.38 (0.13 to 0.66)	0.83	-0.41 (-0.64 to -0.19)	0.70		
WM							
	Pre	0.16 (-0.08 to 0.40)	0.82	-0.17 (-0.52 to 0.19)	1.15	673.00	.157
	Post	0.31 (0.03 to 0.60)	0.97	-0.34 (-0.65 to -0.04)	0.93		
VM							
	Pre	0.00 (-0.29 to 0.30)	0.96	-0.00 (-0.27 to 0.29)	0.93	816.50	.981
	Post	0.28 (-0.02 to 0.60)	0.99	-0.31 (-0.55 to -0.06)	0.78		
Inhibition							
	Pre	0.12 (-0.18 to 0.42)	0.98	-0.13 (-0.42 to 0.16)	0.88	701.00	.265
	Post	0.34 (0.07 to 0.61)	0.89	-0.36 (-0.64 to -0.11)	0.85		
Social cognition							
ToM							
	Pre	4.48 (3.76 to 5.17)	2.39	3.74 (2.92 to 4.56)	2.70	680.50	.187
	Post	5.40 (4.90 to 5.93)	1.70	3.08 (2.49 to 3.67)	1.93		
SP							
	Pre	9.38 (8.15 to 10.72)	4.07	8.69 (7.14 to 10.20)	4.86	733.00	.415

	Post	10.60 (9.32 to 11.75)	3.95	10.69 (9.41 to 11.98)	4.18		
EP							
	Pre	14.88 (13.66 to 16.10)	4.12	14.46 (13.11 to 15.74)	4.20	785.00	.747
	Post	16.26 (15.30 to 17.15)	2.97	13.64 (12.39 to 14.97)	4.23		
Creativity							
Figural Creativity							
	Pre	52.66 (46.57 to 58.91)	21.38	44.62 (39.99 to 49.83)	16.12	655.00	.121
	Post	52.27 (44.97 to 60.54)	24.01	45.43 (41.03 to 49.68)	13.85		
Figural Creative Strengths							
	Pre	2.40 (1.71 to 3.20)	2.39	2.72 (1.76 to 3.85)	3.39	0.49	.624
	Post	2.36 (1.59 to 3.22)	2.62	1.64 (0.97 to 2.41)	2.29		
Verbal Creativity							
	Pre	20.31 (17.33 to 23.68)	10.51	15.22 (12.90 to 17.57)	7.34	560.00	.014
	Post	20.74 (17.11 to 24.33)	11.49	16.79 (13.86 to 19.73)	9.17		

CF = Cognitive Flexibility; PS = Processing Speed; WM = Working Memory; VM =

Verbal Memory; ToM = Theory of Mind; SP = Social Perception; EP = Emotion

Processing. CI = Confidence Interval; SD = Standard Deviation; t = t -test; U = Mann-

Whitney U . CI was derived from the bootstrap analysis.

Supplementary Table 3

Clinical symptoms and functional outcome in the REHACOP and Active Control groups at baseline and post treatment.

REHACOP group			Active control group		Baseline comparison	
	(n = 42)		(n = 39)			
	Mean (95% CI)	SD	Mean (95% CI)	SD	<i>t/U</i>	<i>p</i>
Functional outcome						
Functional competence						
Pre	63.44 (59.39 to 67.34)	13.88	60.68 (56.40 to 65.08)	13.56	0.90	.369
Post	75.31 (72.42 to 78.05)	9.34	63.07 (58.29 to 67.86)	15.25		
Social functioning*						
Pre	24.38 (22.87 to 25.97)	4.82	24.05 (21.71 to 26.37)	5.52	0.23	.816
Post	23.35 (21.77 to 25.03)	5.06	24.15 (22.00 to 26.46)	5.14		
Hedonic capacity*						
Pre	76.38 (71.85 to 80.75)	14.19	78.90 (71.67 to 85.99)	16.23	0.38	.706
Post	74.38 (70.62 to 78.32)	12.98	80.30 (72.90 to 87.60)	17.53		
General self-efficacy*						
Pre	60.35 (53.57 to 67.07)	21.44	58.15 (49.24 to 67.58)	19.77	0.61	.545
Post	61.14 (54.95 to 67.33)	19.09	62.15 (54.68 to 69.71)	17.69		
Clinical symptoms						
Negative						
Pre	28.81 (24.66 to 32.85)	14.11	35.02 (30.85 to 39.41)	13.59	-2.02	.047
Post	22.62 (18.17 to 27.04)	14.53	33.39 (29.15 to 37.95)	13.79		
Positive						
Pre	10.29 (9.10 to 11.57)	4.32	8.72 (7.66 to 9.69)	3.49	1.79	.078
Post	8.67 (7.64 to 9.70)	3.48	8.28 (7.19 to 9.46)	3.69		

Disorganization						
Pre	7.64 (6.77 to 8.58)	3.07	7.70 (6.91 to 8.46)	2.56	-0.09	.927
Post	6.74 (5.88 to 7.64)	2.90	7.58 (6.86 to 8.34)	2.36		
Excitement						
Pre	7.86 (6.76 to 9.16)	3.78	6.98 (6.03 to 8.05)	3.23	727.00	.378
Post	6.50 (5.67 to 7.46)	2.99	6.77 (5.81 to 7.94)	3.44		
Depression						
Pre	6.45 (5.79 to 7.15)	2.39	6.20 (5.51 to 6.94)	2.19	768.50	.629
Post	5.71 (4.98 to 6.48)	2.46	6.04 (5.39 to 6.80)	2.21		

CI = Confidence Interval; SD = Standard Deviation; t = t -test; U = Mann-Whitney U . CI was derived from the bootstrap analysis. *Sample size in these measures was $n = 37$ for the REHACOP group and $n = 20$ for the active control group.

Supplementary Table 4

Differences in change scores between the REHACOP and Active Control groups after controlling for baseline scores.

	REHACOP group (n = 42)		Active control group (n = 39)		ANCOVA for change scores		Effect size
	Mean change score (95% CI)	SE	Mean change score (95% CI)	SE	<i>F</i>	<i>p</i>	η_p^2
Neurocognition							
CF	0.11 (-0.10 to 0.35)	0.11	-0.12 (-0.37 to 0.12)	0.12	2.156	.150	0.027
PS	0.23 (0.09 to 0.37)	0.07	-0.25 (-0.40 to -0.10)	0.08	20.94	.001	0.212
WM	0.24 (-0.00 to 0.48)	0.13	-0.26 (-0.61 to 0.07)	0.17	6.99	.014	0.082
VM	0.28 (0.04 to 0.48)	0.11	-0.30 (-0.51 to -0.11)	0.10	17.35	.001	0.184
Inhibition	0.28 (0.06 to 0.53)	0.12	-0.31 (-0.59 to -0.03)	0.15	11.61	.003	0.130
Social cognition							
ToM	1.12 (0.56 to 1.71)	0.30	-0.88 (-1.43 to -0.42)	0.26	39.78	.001	0.338
SP	1.41 (0.16 to 2.75)	0.66	1.79 (0.55 to 2.92)	0.61	0.22	.645	0.003
EP	1.47 (0.66 to 2.35)	0.43	-0.91 (-1.92 to 0.13)	0.53	14.85	.001	0.160
Creativity							
Figural Creativity	1.25 (-4.12 to 7.49)	2.95	-0.95 (-5.54 to 3.97)	2.45	0.341	.537	0.004

Figural Creative Strengths	-0.12 (-0.74 to 0.56)	0.35	-1.00 (-1.61 to -0.38)	0.31	4.45	.033	0.054
Verbal Creativity	2.43 (-1.09 to 6.32)	1.85	-0.59 (-4.11 to 2.98)	1.83	1.59	.193	0.020
Functional outcome							
Functional competence	12.27 (9.59 to 14.97)	1.36	1.96 (-0.91 to 4.72)	1.41	32.55	.001	0.294
Social functioning*	-0.98 (-2.45 to 0.42)	0.72	0.02 (-1.78 to 1.54)	0.88	0.80	.379	0.015
Hedonic capacity*	-2.25 (-5.62 to 0.93)	1.62	1.86 (-2.95 to 6.99)	2.61	2.11	.194	0.038
General self-efficacy*	1.14 (-4.08 to 6.59)	2.67	3.33 (-3.75 to 9.94)	3.51	0.274	.582	0.005
Clinical symptoms							
Negative	-6.75 (-9.86 to -4.20)	1.45	-1.03 (-3.44 to 1.17)	1.18	9.297	.003	0.108
Positive	-1.41 (-2.19 to -0.54)	0.41	-0.66 (-1.52 to 0.11)	0.41	2.050	.149	0.026
Disorganization	-0.91 (-1.43 to -0.39)	0.27	-0.11 (-0.54 to 0.37)	0.23	5.618	.018	0.067
Excitement	-1.22 (-1.82 to -0.63)	0.30	-0.36 (-1.13 to 0.59)	0.44	2.946	.099	0.036
Depression	-0.70 (-1.35 to 0.03)	0.35	-0.20 (-0.85 to 0.42)	0.32	1.233	.257	0.016

CF = Cognitive Flexibility; PS = Processing Speed; WM = Working Memory; VM = Verbal Memory; ToM = Theory of Mind; SP = Social Perception; EP = Emotion Processing. CI = Confidence Interval; SE = Standard Error; ANCOVA, analysis of covariance; η_p^2 = partial eta

squared; Change scores = post-treatment score - pre-treatment score. Means for change scores are adjusted for the effect of the baseline score. CI and SE for change scores were derived from the bootstrap analysis. Significance levels were determined using F tests based on the bootstrap SE estimate for that comparison, rather than using a pooled SE estimate. *Sample size in these measures was $n = 37$ for the REHACOP group and $n = 20$ for the active control group.